Literature DB >> 20671054

The evolution of melanoma diagnosis: 25 years beyond the ABCDs.

Darrell S Rigel1, Julie Russak, Robert Friedman.   

Abstract

Early detection of malignant melanoma remains the key factor in lowering mortality from this cancer. Recognizing the importance of this issue 25 years ago, our group at New York University published in CA: A Cancer Journal for Clinicians the mnemonic "ABCD" to facilitate the early diagnosis of melanoma. Studies have demonstrated the usefulness of this paradigm in enhancing early melanoma diagnosis as a part of clinical examinations, mass screenings, and public education programs. Approaches to melanoma diagnosis have dynamically evolved during the ensuing quarter century. In the 1990s, dermoscopy enabled the recognition of new subsurface features to differentiate between malignant and benign pigmented lesions. During the last decade, new computer-based technologies have improved diagnostic sensitivity and specificity and may result in optimizing lesion selection for biopsy and pathology review. Despite all of the advances in melanoma diagnosis, timely recognition, detection, and rapid treatment of melanoma remain critical. Although pathologic examination remains the gold standard for diagnosis, this cancer has the potential to be diagnosed through noninvasive approaches because of its cutaneous location. From the development of the ABCDs through current attempts that use complex computer algorithms and genetic markers, a clinician's ability to detect melanoma in its earliest form has been augmented. However, a "good clinical eye" is still fundamental to selecting the lesions for evaluation among the sea of those that are prevalent. As current approaches are refined and new techniques are developed, the improved ability to diagnose this cancer will hopefully enhance reaching the goal of reducing melanoma mortality. Copyright 2010 American Cancer Society, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20671054     DOI: 10.3322/caac.20074

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  83 in total

1.  Sleep duration and sleep-disordered breathing and the risk of melanoma among US women and men.

Authors:  Jeffrey M Cohen; Yunhui T Li; Shaowei Wu; Jiali Han; Abrar A Qureshi; Eunyoung Cho
Journal:  Int J Dermatol       Date:  2015-08-14       Impact factor: 2.736

2.  In Situ Vaccination with Cowpea vs Tobacco Mosaic Virus against Melanoma.

Authors:  Abner A Murray; Chao Wang; Steven Fiering; Nicole F Steinmetz
Journal:  Mol Pharm       Date:  2018-05-25       Impact factor: 4.939

3.  Novice identification of melanoma: not quite as straightforward as the ABCDs.

Authors:  R Benjamin Aldridge; Matteo Zanotto; Lucia Ballerini; Robert B Fisher; Jonathan L Rees
Journal:  Acta Derm Venereol       Date:  2011-03       Impact factor: 4.437

4.  Effect of the disintegrin eristostatin on melanoma-natural killer cell interactions.

Authors:  Stefan Hailey; Elizabeth Adams; Ryan Penn; Alice Wong; Mary Ann McLane
Journal:  Toxicon       Date:  2012-11-09       Impact factor: 3.033

Review 5.  Dermoscopy for melanoma detection in family practice.

Authors:  Andrea Herschorn
Journal:  Can Fam Physician       Date:  2012-07       Impact factor: 3.275

Review 6.  ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease.

Authors:  Francis A Farraye; Gil Y Melmed; Gary R Lichtenstein; Sunanda V Kane
Journal:  Am J Gastroenterol       Date:  2017-01-10       Impact factor: 10.864

7.  A LY-15, a novel cyclic pentapeptide that inhibits B16 cell proliferation and migration and induces cell apoptosis.

Authors:  Xuan Wang; Xiangli Yao; Shiming Fan; Chenshuang Xiang; Runjiao Liu; Juan Feng; Jing Huang; Shouxin Liu
Journal:  Oncol Lett       Date:  2018-02-12       Impact factor: 2.967

Review 8.  miR in melanoma development: miRNAs and acquired hallmarks of cancer in melanoma.

Authors:  Paige E Bennett; Lynne Bemis; David A Norris; Yiqun G Shellman
Journal:  Physiol Genomics       Date:  2013-09-17       Impact factor: 3.107

9.  Comprehensive assessment of the association of ERCC2 Lys751Gln polymorphism with susceptibility to cutaneous melanoma.

Authors:  Yuhao Dong; Le Zhuang; Weiyuan Ma
Journal:  Tumour Biol       Date:  2013-02-03

10.  A possible cross-talk between autophagy and apoptosis in generating an immune response in melanoma.

Authors:  Azim Hossain; Faisal F Y Radwan; Bently P Doonan; Jason M God; Lixia Zhang; P Darwin Bell; Azizul Haque
Journal:  Apoptosis       Date:  2012-10       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.